<DOC>
	<DOCNO>NCT01069094</DOCNO>
	<brief_summary>A study 3 dos Progenta versus placebo versus Lucron Depot treatment leiomyomata .</brief_summary>
	<brief_title>A Study Progenta ( CDB-4124 ) Pre-menopausal Women With Symptomatic Leiomyomata</brief_title>
	<detailed_description>Three dos Progenta ( CDB4124 - 12.5 , 25 , 50 mg ) versus placebo versus Lucron Depot ( leuprolide acetate depot suspension ) initiate female symptomatic leiomyomata . A single dose PK visit conduct subject randomize Progenta arm , screen visit 1 . A second PK assessment conduct Visit 3 ( one month drug ) collect steady state data . Treatment period last 3 month .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Had least one leiomyomata lesion identifiable measurable transvaginal ultrasound . Had regular steady menstrual cycle last 24 36 day . Postmenopausal Subject document endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
</DOC>